tbuckley/cabot-search huggingface dataset:
Response by Methawasin and Granzier to Letter Regarding Article, “Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure With Preserved Ejection Fraction”
Authors: Mei Methawasin, Henk Granzier
Journal: Circulation (2017)
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
Authors: X Leleu, C Kyriakou, I Vande Broek, P Murphy, P Bacon, P Lewis, H Gilet, B Arnould, M T Petrucci
Journal: Blood Cancer Journal (2017)

Abstract Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients’ health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status &gt;2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in &lt;6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort.
Identification of the Multimerin Binding Region within the C2 Domain of Human Factor V Using Constructs Generated by Alanine-Scanning and Site-Directed Mutagenesis.
Authors: Samira B. Jeimy, Rachael A. Woram, Nola Fuller, Mary Anne Quinn-Allen, Gerard Nicolaes, Bjorn Dahlback, William H. Kane, Catherine P.M. Hayward
Journal: Blood (2004)
CHARACTERISTICS AND CLINICAL PREDICTORS OF 11,569 PNEUMOTHORACES ASSOCIATED WITH CARDIAC IMPLANTABLE ELECTRONIC DEVICE PROCEDURES: RESULTS FROM A LARGE NATIONAL DATABASE
Authors: Gbolahan Ogunbayo, Suartcha Prueksaritanond, Odunayo Olorunfemi, Ayman Elbadawi, Deola Saheed, Samy Elayi
Journal: Journal of the American College of Cardiology (2017)
RADIOTRACER IMAGING ALLOWS FOR ASSESSMENT OF SERIAL CHANGES IN ANGIOSOME FOOT PERFUSION FOLLOWING REVASCULARIZATION AND PREDICTS LIMB SALVAGE OUTCOMES IN PATIENTS WITH CRITICAL LIMB ISCHEMIA
Authors: Jessica Buckley, Carlos Mena-Hurtado, Sangchoon Jeon, Xenophon Papademetris, Peter A. Blume, Bauer Sumpio, Albert Sinusas, Mitchel Stacy
Journal: Journal of the American College of Cardiology (2017)
Simone-simulation in medical oncology education: Part I—Pilot feasibility study.
Authors: Shelly Sud, John Kim, Olivia Petersons, Xinni Song, Paul Wheatley-Price, Viren Naik, Martin Neil Reaume
Journal: Journal of Clinical Oncology (2014)

TPS6638 Background: Advances in medical oncology therapeutics have led to increasingly challenging cancer scenarios (CCS), including an expanding spectrum of treatment side effects and chronic cancer complications. There is no defined curriculum addressing CCS management. Simulation based training with debriefing (SBTD) is an educational method utilizing a virtual medium to mimic clinical scenarios. We hypothesize that SBTD, as an educational tool, is better than traditional didactic teaching of CCS management. This unique study tests the feasibility of high-fidelity SBTD in medical oncology education. We eventually aim to develop a national standardized oncology SBTD curriculum to train oncologists in CCS management Methods: With ethics approval, a curriculum highlighting CCS topics was created. Three clinical scenarios were developed and programmed using the high-fidelity SimMan mannequin. Scenarios last 10 minutes, and participants’ decisions determine the course of the scenario. Participants are recruited from medical oncology and internal medicine. After receiving the curriculum, participant demographics are collected and they are randomized 1:1 to intervention Arm A or B. Both arms perform three simulation scenarios. After scenario #1, all participants take a quiz testing CCS-relevant knowledge. Then, Arm A receives an expert-facilitated debriefing; Arm B receives a didactic lecture covering CCS management. The next day all participants perform simulation and quiz #2, with simulation and quiz #3 planned for 8 weeks later. Each simulation is videotaped for two independent reviewers to grade performance using the validated Ottawa Crisis Resource Management Global Rating Scale. Beyond feasibility, outcomes include change in performance and quiz scores, and participants’ satisfaction with educational method as assessed by questionnaire after simulation #2-3. Differences between the three simulation scores in both arms will be calculated, and assessed using independent t-test. At this time, eleven participants have been enrolled and all participants have completed two simulations. Data will be analyzed after the third simulation.
A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer.
Authors: Brian Francis Chapin, Sean Eric Mcguire, Xuemei Wang, Patricia Troncoso, John W. Davis, Neema Navai, Sumit Kumar Subudhi, Amado J. Zurita, John C. Araujo, Curtis Alvin Pettaway, Surena F. Matin, Louis L. Pisters, John Francis Ward, Shi-Ming Tu, Jennifer Wang, Ott Le, Christopher Logothetis, Ana Aparicio
Journal: Journal of Clinical Oncology (2015)

TPS5075 Background: Treatment for metastatic (M1) prostate cancer (PC) is centered on the use of systemic therapy. Evidence suggests that definitive treatment of the primary tumor (DTPT) may improve outcomes of men with advanced disease. In addition to prevention of symptomatic local progression there is evidence that local therapy may alter disease biology. Thus, DTPT may delay local and distant progression, prolong time to castration resistant PC (CRPC) and fatal metastatic burden. We sought to test the hypothesis that DTPT added to BST will delay time to CRPC in men presenting with M1 PC. Methods: After completing 6 months of BST (any standard therapy for M1 PC) 120 men will be randomized 1:1 to continue BST +/- DTPT. Patients are stratified by PSA nadir at randomization ( ≤ 4 and > 4) and by treatment center. Type of DTPT is based on patient preference and physician recommendations. Patients are evaluated every 3 months with a history and physical exam and serum PSA. Progressive disease is defined per the PCWG2. A Bayesian design with interim monitoring will be implemented. After a minimum of 60 patients have been randomized, if at any time, the probability of one arm (A) is better than the other arm ( B) is greater than 97.5%, the trial will be stopped early and A will be selected as superior. Patients will be followed for a minimum 24 months before a final analysis is conducted. Eligibility: Prostate adenocarcinoma with documented evidence of M1 disease per AJCC v6. Patients must have castrate sensitive disease at randomization and have not received BST for > 6 months prior to randomization. Exclusions include small cell carcinoma, brain metastases or CRPC within 6 months of initiating BST. Enrollment: 35 patients are enrolled to date and 20 have been randomized. 8 patients developed CRPC prior to the 6 month time point. The protocol is scheduled to open at 3 additional sites by spring 2015. Correlative Studies: Characterization of the prostate tumor and tumor microenvironment (stromal and immunologic components) and associated changes on magnetic resonance imaging will be used to identify a biomarker panel to predict benefit from DTPT. Clinical trial information: NCT01751438.
Abstract 15353: Recombinant Human Growth Hormone Diminishes Cell Injury, Remodeling and Ventricular Dysfunction in Dilated Cardiomyopathy in Young Rat
Authors: Shengquan Cheng, Huan Qiang, Kaili Pan, Shuping Ge
Journal: Circulation (2013)

Background and Objectives: Although there is conflicting evidence in the beneficial effects of recombinant human growth hormone (rhGH) for dilated cardiomyopathy (DCM) in adults, data suggest that it may be efficacious for DCM in children. We sought to test the hypothesis that rhGH restores the GH/insulin-like growth factor-1 (IGF-1) axis and facilitates cell growth, repair, and functional and hemodynamic improvement for DCM in the young.

Methods: A total of 60 two-week old SD rats were randomized into 3 groups. DCM was induced by Furazolidone (0.25 mg/g) administered gastrically in Group 1 (Treatment: rhGH: 0.15u/kg IP QD) and Group 2 (Placebo: Normal Saline IP QD), and compared with Group 3 (Control). Twelve weeks after the treatment, echocardiography, cardiac catheterization, serum markers, and postmortem histopathology were obtained for analysis.

Results: Following treatment, the body weight, IGF-1, and IGF binding protein-3 (IGFBP-3) increased in Group 1 than Group 2 and 3. Cardiac troponin I and T and N-terminal pro-brain natriuretic peptide decreased in Group 1 than Group 2. Left ventricular (LV) cavity sizes decreased but wall thickness, fractional shortening (FS) and ejection fraction (EF) increased in Group 1 than Group 2 by echocardiography (FS: Group 1: 45.7±8.2% vs Group 2: 37.0±8.5% vs Group 3: 51.5±7.3%, P<0.0001, and EF: Group 1: 79.1±15.4% vs Group 2: 48.2±13.2% vs Group 3: 85.4±14.3%, P<0.0001). Furthermore, central venous pressure, LV end diastolic pressure and heart rate were lower in Group 1 than Group 2. Histopathology showed cell injury, fibrosis, and remodeling in Group 2, which were significantly less in Group 1.

Conclusions: Our study suggests that rhGH augments GH/IGF axis, diminishes cell injury, fibrosis, and remodeling, therefore, improves LV size, wall thickness, systolic function and hemodynamics in young rats with DCM. Further investigation and clinical trial is warranted to validate the efficacy of this therapy for DCM in children.
INFECTIVE ENDOCARDITIS FOLLOWING TRANSCUTANEOUS AORTIC VALVE IMPLANTATION: CLINICAL, ECHOCARDIOGRAPHIC AND HEMODYNAMIC FEATURES
Authors: William Miranda, Heidi Connolly, Larry Baddour, Kashish Goel, Walter Wilson, Kevin Greason, Charanjit Rihal, David Holmes, Vuyisile Nkomo, Mahmoud Ali, Jae Oh, Sorin Pislaru
Journal: Journal of the American College of Cardiology (2017)
ACUTE KIDNEY INJURY IS HIGHLY FREQUENT EARLY AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION WITH HIGH MORBIDITY AND MORTALITY RATES: A MULTICENTRE STUDY
Authors: Rahat Muslem, Kadir Caliskan, Sakir Akin, Dennis A. Hesselink, Glen J.R. Withman, Ryan Tedford, Ad J.J.C. Bogers, Olivier Manintveld, Stuart Russell
Journal: Journal of the American College of Cardiology (2017)
LONG TERM OUTCOMES AND RISK STRATIFICATION IN ATRIAL FIBRILLATION PATIENTS WITH LOW RISK CHADS2 ≤1 WITH ANTITHROMBOTIC THERAPY
Authors: Anjani Golive, Heidi May, Tami Bair, Victoria Jacobs, Brian Crandall, Michael J. Cutler, John Day, Charles Mallender, Jeffrey S. Osborn, Jonathan Weiss, T. Jared Bunch
Journal: Journal of the American College of Cardiology (2017)
Early hemoglobin decline and survival prognosis in epoetin alfa studies
Authors: J. A. Berlin, P. J. Bowers, S. Rao, S. Sun, K. Liu, D. H. Henry
Journal: Journal of Clinical Oncology (2009)

9625 Background: When cancer patients (pts) with chemotherapy-induced anemia (CIA) respond to erythropoietic-stimulating agents (ESA), hemoglobin (Hb) typically increases within 4–8 weeks. This exploratory analysis examined whether mortality differs depending on Hb response after 4 or 8 weeks of epoetin alfa (EPO) treatment or depending on transfusion. Methods: Pt-level data were analyzed from 31 randomized studies (7,215 pts) of epoetin alfa vs non-EPO (15 studies) or placebo (16 studies) in pts with CIA. A landmark analysis was used; Hb change was set at a specific time (4 and 8 weeks) and subsequent survival was examined separately for EPO and placebo. Pts were categorized as “Hb increased” (&gt;0.5 g/dL), “Hb decreased” (&gt;0.5 g/dL), or “Hb stable” (within ±0.5 g/dL) compared to baseline. Hb stable was compared to other Hb change categories with Cox proportional hazards models, stratified by study and adjusted for potential confounders. Results: The hazard ratio (HR) for Hb decreased versus Hb stable at 4 weeks was 1.44 for EPO (95% CI: 1.04, 1.99), indicating worse survival for pts with a decline in Hb. This association was weaker for placebo (HR: 1.12; 95% CI: 0.74, 1.67). Increased risk with declining Hb in EPO-treated pts was most pronounced in studies that maintained Hb ≥12 g/dL or treated pts for &gt;12–16 weeks (1,876 pts). Patterns were similar using the 8-week landmark. In both EPO-treated and placebo pts, transfusion increased the rate of on-study death ∼3.5 fold (treating transfusion as a time-dependent variable). Conclusions: These exploratory findings suggest that both decreased Hb after 4 or 8 weeks of EPO treatment and transfusion are associated with increased risk of death. In spite of adjustment for other prognostic factors, it is likely that this association reflects poorer underlying prognosis of pts whose Hb fails to respond. ESAs should be discontinued in the absence of a Hb response. [Table: see text]
RENAL REPLACEMENT THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: RATE OF USE, CLINICAL PREDICTORS AND RELATIONSHIP WITH IN-HOSPITAL MORTALITY
Authors: Giancarlo Silvio Marenzi, Nicola Cosentino, Jeness Campodonico, Marco Moltrasio, Valentina Milazzo, Mara Rubino, Milena Cecere, Susanna Mosca, Monica De Metrio, Ivana Marana, Marco Grazi, Gianfranco Lauri, Antonio Bartorelli
Journal: Journal of the American College of Cardiology (2017)
INCIDENCE AND PROGNOSTIC IMPLICATIONS OF THE PRESENCE OF MULTIPLE COMPLEX PLAQUES IN SURVIVORS OF ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Jaclyn Carberry, David Carrick, Caroline Haig, Margaret McEntegart, Mark Petrie, M. Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmad Mahrous, Aadil Shaukat, Ian Ford, Keith Oldroyd, Colin Berry
Journal: Journal of the American College of Cardiology (2017)
Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG.
Authors: Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, Kumi Tsuruhata, Chisato Endo, Mari Muto, Chie Emuta, Yukiko Chisaka, Munetake Shimabe, Hiroshi Miyazaki, Shiro Kataoka
Journal: Blood (2006)
INFLUENZA EPIDEMICS ARE ASSOCIATED WITH AN INCREASED RISK OF VENTRICULAR ARRHYTHMIA THERAPIES IN PATIENTS WITH IMPLANTABLE CARDIAC DEFIBRILLATORS OR CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS
Authors: Mohammad Madjid, Allison T. Connolly, Yelena Nabutovsky, Payam Safavi-Naeini, Charles C. Miller
Journal: Journal of the American College of Cardiology (2017)
Feasibility and results of a randomized phase Ιb study of fractionated <sup>90</sup>Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.
Authors: Vincent J. Picozzi, Ramesh K. Ramanathan, Maeve Aine Lowery, Allyson J. Ocean, Edith P. Mitchell, Bert H. O'Neil, Michael J. Guarino, Paul R. Conkling, Steven J. Cohen, Nathan Bahary, Richard C. Frank, Tomislav Dragovich, Benjamin B. Bridges, Fadi S. Braiteh, Fa-Chyi Lee, Thomas Edward Gribbin, Donald A. Richards, Alexander Starodub, William A. Wegener, David M. Goldenberg
Journal: Journal of Clinical Oncology (2014)

4026 Background: Radioimmunotherapy (RAIT) is an option to avoid side effects of further chemotherapy for advanced metastatic pancreatic ductal cancer (mPC). This multicenter, phase Ib study aimed at determining the contribution of low radiosensitizing doses of gemcitabine (GEM) to fractionated doses of 90Y-clivatuzumab tetraxetanin pts with mPC after ≥ 2prior GEM- or 5FU-containing regimens. Methods: Pts were randomized to Arm A (4-week cycles: 200 mg/m2 GEM, weekly, combined with 6.5 mCi/m2 90Y-clivatuzumab tetraxetan, once-weekly the last 3 weeks) or Arm B (3-week cycles: 6.5 mCi/m2 90Y-clivatuzumab tetraxetan alone, once-weekly), repeating cycles after 4-week delays until unacceptable toxicity or pt deterioration. Safety and efficacy were evaluated. Results: Fifty-eight pts (33M/25F; median age 63.5) were treated on arm A (N=29) or B (N=29), 1.6 median years from diagnosis with a median of 3 (2-7) prior treatments. The main toxicity was transient myelosuppression, as expected, with dose reductions for cytopenias (cycle 1, 14%; cycle ≥ 2, 70%) limiting the number of Grade 3-4 events per cycle (thrombocytopenia, 13%; neutropenia, anemia, <7%). Serious events (thromboembolism, coagulopathy, infection) in 6 pts were felt to be consistent with known risks in mPC. A total of 53/58 pts (27 Arm A, 26 Arm B, 91% overall) completed ≥1 full treatment cycle and thus were evaluable. Pts terminated further treatment due to disease progression, with 23 pts (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including 7 pts (6 Arm A, 1 Arm B; 12%) with 3-7 cycles. Two pts in Arm A had PRs by RECIST. Kaplan-Meier median overall survival (OS) was 119 days (30-508) in Arm A v 84 days (27-287) in Arm B (hazard ratio 0.54, 95% CI: 0.27-0.87; P=0.020, log-rank). The median OS for Arm A v Arm B increased to 240 v 103 days with multiple cycles (P= 0.004) and 3 pts in Arm A still being observed (11 – 17 mos). Conclusions: This is the first randomized trial completed in mPC pts having ≥ 2 prior therapies. Fractionated RAIT with 90Υ-clivatuzumab tetraxetan and low-dose gemcitabineappears promising in this population, supporting Phase 3 studies of this combination now being initiated. Clinical trial information: NCT01510561.
Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Authors: Victoria Meucci Villaflor, Ezra E. W. Cohen, James M Melotek, Ryan J Brisson, Theodore Karrison, Elizabeth A. Blair, Louis Portugal, Kerstin Stenson, Jonas A. De Souza, Alexander Langerman, Tanguy Y. Seiwert, Everett E. Vokes, Daniel J. Haraf
Journal: Journal of Clinical Oncology (2015)

6050 Background: Risk stratified treatment approaches are needed in LA-HNSCC. This study determined if RT volumes can be significantly reduced in IC responders without compromising disease control. Methods: Patients (pt) with measurable LA-HNSCC regardless of HPV status were treated with 2 cycles of IC (cisplatin 75 mg/m2, paclitaxel 175 mg/m2 day 1, and weekly cetuximab, with or without everolimus). Response to IC determined the extent of RT reduction. Pt with “good” response (GR), ≥ 50% reduction in the sum of gross tumor diameters, received TFHX (paclitaxel, fluorouracil, hydroxyurea, and twice daily RT to 75 Gy), with the planning target volume (PTV1) encompassing exclusively gross disease (RAVD). Pt with < 50% response (NR) were treated with volumes encompassing PTV1 and the next nodal station at risk (PTV2) to 45 Gy, followed by a sequential boost to PTV1 to 75 Gy. Results: 94 pt were enrolled 5/2010 – 3/2014, median age 58 (range 27-76), 84% male, 58 pts HPV+ oropharynx (OP), 11 pt HPV- OP, 53% >10pk yrs tobacco use, 97% stage IV (56% T3/T4, 84% ≥ N2b). Everolimus was discontinued for futility at interim analysis after 25 pt. There were 37 (39%) GR to IC.At a median follow-up of 2 years, 79 pts are alive, 20 patients experienced failure. Site of first failure was locoregional in 10 (1 GR, 9 NR), distant in 7 (2 GR, 5 NR), and both in the remaining 3 pt (1 GR, 2 NR). Ultimate LRC was 91.5% on intention to treat analysis. Of 15 pts who experienced a component of LRF at any time, 14 (2 GR, 12NR) were within the RT treatment volume. One GR experienced LRF both within and outside the treated RT volume. Acute grade 3+ toxicities included 10% neutropenia, 22% dermatitis, 53% stomatitis. Rate of gastrostomy tubes (PEG) placement was 24% less during RT and 14% less at 1-yr follow up in RAVD pt. Conclusions: RAVD is a novel approach that uses response to IC to guide extent of RT volume reduction in both HPV (+) and (-) LA-HNSCC. In this trial, it appears that outcomes with RAVD are not compromised and long term toxicity may be improved. Further investigation is warranted. Clinical trial information: NCT01133678. 1-year 2-year OS 88.4% + 3.5 80.8% + 4.6 PFS 87.6% + 3.5 79.1% + 4.6 GR- PFS 89% + 5.1 86% + 5.8 NR-PFS 79% + 5.8 70% + 7.3
Conditioning without Antibiotic Prophylaxis May Not Increase Infection Related Mortality in Allogeneic Hematopoeitic Stem Cell Transplantation
Authors: Aj ay Sharma, Velu Nair, Satyaranjan Das, Deepak Kumar Mishra, Jyoti Kotwal, Naveen Grover, Ridhima Dabas, O P Mathew
Journal: Blood (2008)
Abstract 18772: Impact of Hematoma After Pacemaker Implantation: An Analysis of a Nationwide Database of 77,074 Patients
Authors: Arun Raghav Mahankali Sridhar, Madhu Reddy, Ajay Vallakati, Ryan Maybrook, Loren Berenbom, Buddhadeb Dawn, Dhanunjaya Lakkireddy
Journal: Circulation (2013)

Introduction: Pocket hematoma is one of the most common complications associated with pacemaker implantation. We sought to identify the incidence of pocket hematoma after a de novo pacemaker implantation and evaluate its impact on the hospital outcomes using a large all-payer national inpatient database. Methods: Data from Nationwide Inpatient Sample 2010 was used to identify all hospitalizations for a pacemaker implantation. All primary implantations of single chamber, dual chamber and biventricular pacemakers during the year 2010 were identified using the appropriate ICD-9 codes. We then identified the patients who experienced a procedure related hematoma during the hospital stay. We then compared the outcomes of the patients with and without a hematoma complication. All analyses were performed using SPSS 20 complex samples using appropriate weights to adjust for the complex sampling design of the national database. Results: Out of a total of 77,074 primary pacemaker implantations in the year 2010, 1677 (2.1%) of the implantations were complicated by a hematoma. Patients with biventricular pacemakers were more likely to develop a hematoma than single or dual chamber pacemakers (2.7% vs 1.5%; p&lt;0.001). No other demographic variables or hospital categories were associated with a hematoma formation. Patients who developed a hematoma had a higher mortality (2.0% vs 0.7%, p&lt;0.001), longer hospital length of stay (8.7 days vs 4.8 days, p&lt;0.001) and higher in-hospital charges ($155,071 vs $108,225, p&lt;0.001) compared to patients who did not develop a hematoma. The adverse outcomes associated with hematoma were noted with all the pacemaker sub-types. Conclusions: Hematoma is an uncommon complication associated with pacemaker implantation and adversely impacts in-hospital outcomes.